Clinical Trial Update: Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial [Phase 3]

View source ↗

Summary

Phase 3 trial update on CKDB-501A shows efficacy and safety in treating moderate-to-severe glabellar lines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Lines

Drugs mentioned

• CKDB-501A

Snippet

Sponsor: CKD Bio Corporation | Conditions: Glabellar Lines | Phase 3 | Status: COMPLETED